|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | ABO incompatible renal transplants:Good or bad?显示文摘ABO incompatible kidney transplantation(ABOi-KT) was previously considered to be an absolute contraindication for patients with end-stage kidney disease(ESKD) due to hyperacute rejection related to blood type barrier. Since the first successful series of ABOi-KT was reported, ABOi-KT is performed increasingly all over the world. ABOi-KT has led to an expanded donor pool and reduced the number of patients with ESKD awaiting deceased kidney transplantation(KT). Intensified immunosuppression and immunological understanding has helped to shape current desensitization protocols. Consequently, in recent years, ABOi-KT outcome is comparable to ABO compatible KT(ABOc-KT). However, many questions still remain unanswered. In ABOi-KT, there is an additional residual immunological risk that maylead to allograft damage, despite using current diverse but usually intensified immunosuppressive protocols at the expense of increasing risk of infection and possibly malignancy. Notably, in ABOi-KT, desensitization and antibody reduction therapies have increased the cost of KT. Reassuringly, there has been an evolution in ABOiKT leading to a simplification of protocols over the last decade. This review provides an overview of the history, outcome, protocol, advantages and disadvantages in ABOi-KT, and focuses on whether ABOi-KT should be recommended as a therapeutic option of KT in the future. | Masaki Muramatsu Hector Daniel Gonzalez Roberto Cacciola Atsushi Aikawa Magdi M Yaqoob Carmelo Puliatti | 2014 | World Journal of Transplantation2014，4，1： | 18 |
| 2 | Living transplanta-tion using a kidney with a large cyst as curative treatment ofdonor’s hypertension显示文摘 | Veroux P Veroux M Puliatti C | 2002 | Nephrol Dial Transplant2002，17，12： | 1 |
| 3 | Early de novo malignancies after kidney transplantation 显示文摘 | Veroux M Puliatti C Fiamingo P | 2004 | Transplant Proc2004，36，3： | 1 |
| 4 | Outcome and cost analysis of induc- tion immunosuppression with IL2Mab or ATG in DCD kidney trans- plants 显示文摘 | Popat R Syed A Puliatti C | 2014 | Transplantation2014，97，11： | 1 |
| 5 | Early de novo malignancies after kidney transplantation显示文摘 | M Veroux C Puliatti P Fiamingo D Cappello M Macarone D Puliatti D Vizcarra M Gagliano P Veroux | 2004 | Transplantation Proceedings2004，，3： | 1 |
| 6 | Living transplantationusing a kidney with a large cyst as curative treatment ofdonor'shypertension显示文摘 | Veroux P Veroux M Puliatti C | 2002 | Nephrol Dial Transplant2002，17，12： | 1 |
| 7 | Artificial intelligence for renal cancer:From imaging to histology and beyond显示文摘Artificial intelligence(AI)has made considerable progress within the last decade and is the subject of contemporary literature.This trend is driven by improved computational abilities and increasing amounts of complex data that allow for new approaches in analysis and interpretation.Renal cell carcinoma(RCC)has a rising incidence since most tumors are now detected at an earlier stage due to improved imaging.This creates considerable challenges as approximately 10%e17%of kidney tumors are designated as benign in histopathological evaluation;however,certain co-morbid populations(the obese and elderly)have an increased peri-interventional risk.AI offers an alternative solution by helping to optimize precision and guidance for diagnostic and therapeutic decisions.The narrative review introduced basic principles and provide a comprehensive overview of current AI techniques for RCC.Currently,AI applications can be found in any aspect of RCC management including diagnostics,perioperative care,pathology,and follow-up.Most commonly applied models include neural networks,random forest,support vector machines,and regression.However,for implementation in daily practice,health care providers need to develop a basic understanding and establish interdisciplinary collaborations in order to standardize datasets,define meaningful endpoints,and unify interpretation. | Karl-Friedrich Kowalewski Luisa Egen Chanel E.Fischetti Stefano Puliatti Gomez Rivas Juan Mark Taratkin Rivero Belenchon Ines Marie Angela Sidoti Abate Julia Muhlbauer Frederik Wessels Enrico Checcucci Giovanni Cacciamani | 2022 | Asian Journal of Urology2022，9，3： | 0 |
| 8 | New imaging technologies for robotic kidney cancer surgery显示文摘Objective:Kidney cancers account for approximately 2%of all newly diagnosed cancer in 2020.Among the primary treatment options for kidney cancer,urologist may choose between radical or partial nephrectomy,or ablative therapies.Nowadays,robotic-assisted partial nephrectomy(RAPN)for the management of renal cancers has gained popularity,up to being considered the gold standard.However,RAPN is a challenging procedure with a steep learning curve.Methods:In this narrative review,different imaging technologies used to guide and aid RAPN are discussed.Results:Three-dimensional visualization technology has been extensively discussed in RAPN,showing its value in enhancing robotic-surgery training,patient counseling,surgical planning,and intraoperative guidance.Intraoperative imaging technologies such as intracorporeal ultrasound,near-infrared fluorescent imaging,and intraoperative pathological examination can also be used to improve the outcomes following RAPN.Finally,artificial intelligence may play a role in the field of RAPN soon.Conclusion:RAPN is a complex surgery;however,many imaging technologies may play an important role in facilitating it. | Stefano Puliatti Ahmed Eissa Enrico Checcucci Pietro Piazza Marco Amato Stefania Ferretti Simone Scarcella Juan Gomez Rivas Mark Taratkin Jose Marenco Ines Belenchon Rivero Karl-Friedrich Kowalewski Giovanni Cacciamani Ahmed El-Sherbiny Ahmed Zoeir Abdelhamid MEl-Bahnasy Ruben De Groote Alexandre Mottrie Salvatore Micali | 2022 | Asian Journal of Urology2022，9，3： | 0 |
| 9 | Incidence, risk factors, and outcome of BK polyomavirus infection after kidney transplantation显示文摘BACKGROUND Polyomavirus-associated nephropathy is a leading cause of kidney allograft failure. Therapeutic options are limited and prompt reduction of the net state of immunosuppression represents the mainstay of treatment. More recent application of aggressive screening and management protocols for BK-virus infection after renal transplantation has shown encouraging results. Nevertheless,long-term outcome for patients with BK-viremia and nephropathy remains obscure. Risk factors for BK-virus infection are also unclear.AIM To investigate incidence, risk factors, and outcome of BK-virus infection after kidney transplantation.METHODS This single-centre observational study with a median follow up of 57(31-80) mo comprises 629 consecutive adult patients who underwent kidney transplantation between 2007 and 2013. Data were prospectively recorded and annually reviewed until 2016. Recipients were periodically screened for BK-virus by plasmaquantitative polymerized chain reaction. Patients with BK viral load ≥ 1000 copies/mL were diagnosed BK-viremia and underwent histological assessment to rule out nephropathy. In case of BK-viremia, immunosuppression was minimized according to a prespecified protocol. The following outcomes were evaluated: patient survival, overall graft survival, graft failure considering death as a competing risk, 30-d-event-censored graft failure, response to treatment,rejection, renal function, urologic complications, opportunistic infections, newonset diabetes after transplantation, and malignancies. We used a multivariable model to analyse risk factors for BK-viremia and nephropathy.RESULTS BK-viremia was detected in 9.5% recipients. Initial viral load was high(≥ 10000 copies/mL) in 66.7% and low(< 10000 copies/mL) in 33.3% of these patients.Polyomavirus-associated nephropathy was diagnosed in 6.5% of the study population. Patients with high initial viral load were more likely to experience sustained viremia(95% vs 25%, P < 0.00001), nephropathy(92.5% vs 15%, P <0.00001), and polyomavirus-related graft loss(27.5% vs 0%, P = 0.0108) than recipients with low initial viral load. Comparison between recipients with or without BK-viremia showed that the proportion of patients with Afro-Caribbean ethnicity(33.3% vs 16.5%, P = 0.0024), panel-reactive antibody ≥ 50%(30% vs14.6%, P = 0.0047), human leukocyte antigen(HLA) mismatching > 4(26.7% vs13.4%, P = 0.0110), and rejection within thirty days of transplant(21.7% vs 9.5%; P= 0.0073) was higher in the viremic group. Five-year patient and overall graft survival rates for patients with or without BK-viremia were similar. However,viremic recipients showed higher 5-year crude cumulative(22.5% vs 12.2%, P =0.0270) and 30-d-event-censored(22.5% vs 7.1%, P = 0.001) incidences of graft failure than control. In the viremic group we also observed higher proportions of recipients with 5-year estimated glomerular filtration rate < 30 mL/min than the group without viremia: 45% vs 27%(P = 0.0064). Urologic complications were comparable between the two groups. Response to treatment was complete in55%, partial in 26.7%, and absent in 18.3% patients. The nephropathy group showed higher 5-year crude cumulative and 30-d-event-censored incidences of graft failure than control: 29.1% vs 12.1%(P = 0.008) and 29.1% vs 7.2%(P <0.001), respectively. Our multivariable model demonstrated that Afro-Caribbean ethnicity, panel-reactive antibody > 50%, HLA mismatching > 4, and rejection were independent risk factors for BK-virus viremia whereas cytomegalovirus prophylaxis was protective.CONCLUSION Current treatment of BK-virus infection offers sub-optimal results. Initial viremia is a valuable parameter to detect patients at increased risk of nephropathy. Panelreactive antibody > 50% and Afro-Caribbean ethnicity are independent predictors of BK-virus infection whereas cytomegalovirus prophylaxis has a protective effect. | Evaldo Favi Carmelo Puliatti Rajesh Sivaprakasam Mariano Ferraresso Federico Ambrogi Serena Delbue Federico Gervasi Ilaria Salzillo Nicholas Raison Roberto Cacciola | 2019 | World Journal of Clinical Cases2019，7，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员